Cogent Biosciences Inc (COGT) - Total Liabilities
Based on the latest financial reports, Cogent Biosciences Inc (COGT) has total liabilities worth $301.24 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Cogent Biosciences Inc (COGT) liquidity interval to measure how many days the company can operate on defensive assets alone.
Cogent Biosciences Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Cogent Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check COGT financial resilience to evaluate the company's liquid asset resilience ratio.
Cogent Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Cogent Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Compagnie Generale des Etablissements Michelin SCA
LSE:0OFM
|
UK | €18.39 Billion |
|
Maase Inc.
NASDAQ:MAAS
|
USA | $61.15 Million |
|
Pampa Energia SA
BA:PAMP
|
Argentina | AR$3.71 Billion |
|
Parkland Fuel Corporation
TO:PKI
|
Canada | CA$10.44 Billion |
|
Iridium Communications Inc
NASDAQ:IRDM
|
USA | $2.09 Billion |
|
APT Medical Inc
SHG:688617
|
China | CN¥423.40 Million |
|
LS Corp
KO:006260
|
Korea | ₩15.65 Trillion |
|
EPAM Systems Inc
NYSE:EPAM
|
USA | $1.05 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Cogent Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cogent Biosciences Inc balance sheet assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cogent Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cogent Biosciences Inc (2015–2025)
The table below shows the annual total liabilities of Cogent Biosciences Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $301.24 Million | +320.65% |
| 2024-12-31 | $71.61 Million | +28.72% |
| 2023-12-31 | $55.63 Million | +23.43% |
| 2022-12-31 | $45.08 Million | +151.70% |
| 2021-12-31 | $17.91 Million | +10.21% |
| 2020-12-31 | $16.25 Million | -8.00% |
| 2019-12-31 | $17.66 Million | -31.26% |
| 2018-12-31 | $25.69 Million | +23.46% |
| 2017-12-31 | $20.81 Million | -10.15% |
| 2016-12-31 | $23.16 Million | -8.27% |
| 2015-12-31 | $25.25 Million | -- |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more